Our Review Summary
This news release focuses on a study of a new drug, tivanisiran, to treat dry eyes that was presented at a recent medical conference. It mentions the completion of both phase I and phase 2 trials and the start of a phase 3 trial, but it neglects to provide any of the details of the research. There is nothing offered about costs, the benefits or the harms of using the drug. It refers to the terms of “dry eye disease” or “dry eyes syndrome” repeatedly even though these are not recognized medical conditions.
Why This Matters
When it comes to health and medical news, journalists and other members of the public deserve useful information that can be used to evaluate a new treatment. The research summarized here is in far too early a stage to warrant distributing a news release.
Criteria
Not Satisfactory
There is no discussion of the potential cost of this new medication, tivanisiran. We do know, however, that current other treatments for dry eyes can be expensive. Cyclosporine A drops, for example, may run as high as $400 a month. There is no indication that tivanisiran might be more affordable to patients, or if insurers might cover the cost of this news drug.
Not Satisfactory
There is no effort made in this release to provide any numbers that would put the benefits of using tivanisiran in context. It does quote a scientist working on the treatment endorsing the drug:
According to Ana Isabel Jiménez, Director of R&D at Sylentis, “we trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world.”
Not Satisfactory
Likewise, there is no mention of potential harms that use of tivanisiran might cause to patients. Since one of the earlier studies was a safety trial it would have been appropriate to include those results in the release.
Not Satisfactory
There is no evidence included in the release, despite the headline that says the drugmaker “announces the results of tivanisiran for dry eye syndrome.” The release only notes that the drug completed both phase I and phase 2 trials, (for safety and optimum dosage) and that a phase 3 trial is starting.
The release doesn’t point readers to any of the earlier trials. It should be noted that these results were reported at a medical conference and have not been peer-reviewed or published in a medical journal.
Not Satisfactory
This release crosses the line into disease mongering with its repeat references to “dry eye disease” and “dry eye syndrome” which are not recognized medical conditions. Dry eyes can be caused by numerous things, ranging from side effects of medications to normal aging.
Satisfactory
PharmaMar, the parent company of he drugmaker, is listed as the study funder on the EurkekAlert! website which hosts the news release. We encourage news releases to include sponsors and conflict of interest information in the body of the news release so that information follows when the release is picked up verbatim by news aggregators.
Satisfactory
The release mentions alternatives to tivanisiran:
“Dry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general. However, the main treatment consists of artificial tears, in the form of drops, gel or creams. Preservative-free eye drops have generally been found to offer the best long-term response.”
The American Optometric Association publishes a patient pamphlet that provides additional management options.
Satisfactory
A scientist working for the drugmaker says she hopes “that tivanisiran will soon become a real alternative.” Savvy readers will note that the drug is still in development and that the drug is not yet ready for patient use outside of a research setting.
Satisfactory
This treatment, at least for dry eye, is novel since it is using a different approach to dealing with dry eyes than currently available medications use. But it’s important to keep in mind that the treatment is still preliminary and must be studied in larger trials before being submitted for FDA approval.
Satisfactory
The unjustifiable use of the terms “dry eye disease” and “dry eye syndrome” have already been addressed under the Disease Mongering criteria.
Total Score: 5 of 10 Satisfactory
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like